Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Overview of attention for article published in Advances in Therapy, August 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news: 1 news outlet
twitter: 4 X users

patent: 1 patent
guideline: 2 clinical guideline sources

So far, Altmetric has seen 5 X posts from 4 X users, with an upper bound of 44,425 followers.

Cardiovascular risks, bleeding risks, and clinical events from 3 phase III trials of pirfenidone in patients with #IPF: https://t.co/3to7Nxnoes

RT @atscommunity: Cardiovascular risks, bleeding risks, and clinical events from 3 phase III trials of pirfenidone in patients with #IPF: h…

Cardiovascular risks, bleeding risks, and clinical events from 3 phase III trials of pirfenidone in patients with #IPF: https://t.co/3to7Nxnoes

RT @AdvancesTherapy: Just published: "Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of #Pirfenidone in…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 1 additional X posts.